Skip to main content
SpringerLink
Log in
Book cover

Nontuberculous Mycobacterial Disease pp 401–411Cite as

Management of Lung Diseases Associated with NTM Infection

  • Chapter
  • First Online:

  • 935 Accesses

Part of the book series: Respiratory Medicine ((RM))

Abstract

A variety of lung diseases are either the cause or the consequence of nontuberculous mycobacterial (NTM) infections. The most common of these diseases are COPD, bronchiectasis, and fibrotic lung disease. Identifying and treating underlying lung diseases and coexisting infections with bacteria, fungi, and other organisms are critical elements for mitigating the impact of the NTM infection. The quality of life of patients with NTM infection can be improved by addressing coexisting lung disease and other complicating factors that contribute to morbidity and possibly mortality. A multimodality therapeutic approach and a collaborative approach between treating clinicians can maximize therapeutic benefit to the individual patient.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Rosenzweig DY. Pulmonary mycobacterial infections due to mycobacterium intracellulare-avium complex. Chest. 1979;75:115–9.

    Article  CAS  Google Scholar 

  2. Wolinsky E. Nontuberculous mycobacterium and associated diseases. Am Rev Respir Dis. 1979;119:107–59.

    CAS  PubMed  Google Scholar 

  3. Andrejak C, Nielsen R, Thomsen VO, Duhaut P, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256–62.

    Article  Google Scholar 

  4. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185:881–6.

    Article  Google Scholar 

  5. Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc. 2015;12:642–7.

    Article  Google Scholar 

  6. Olivier KN, Weber DJ, Wallace RJ, Faiz AR, et al. Nontuberculous mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828–34.

    Article  Google Scholar 

  7. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacterium. Current state and new insights. Chest. 2015;148:1517–27.

    Article  Google Scholar 

  8. Ito Y, Hirai T, Fujita K, Maekawa K, et al. Increasing patients with pulmonary mycobacterium avium complex disease and associated underlying disease in Japan. J Infect Chemother. 2015;21:352–6.

    Article  Google Scholar 

  9. Brode SK, Jamieson FB, Ng R, et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario Canada. Chest. 2014;146:563–72.

    Article  Google Scholar 

  10. Lim J, Lyu J, Choi C-M, Oh Y-M, et al. Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules. Int J Tuberc Lung Dis. 2010;14:1635–40.

    CAS  PubMed  Google Scholar 

  11. Khoor A, Leslie KO, Tazelaar HD, Helmers RA, Colby TV. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol. 2001;115:755–62.

    Article  CAS  Google Scholar 

  12. Char A, Hopkinson NS, Hansell DM, Nicholson AG, et al. Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histologic assessment of specimens: a cohort study. BMC Pulm Med. 2014;12:124.

    Article  Google Scholar 

  13. Aitken MB, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185:231–2.

    Article  CAS  Google Scholar 

  14. Bryant JM, Grogono DM, Greaves D, Foweraker J, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381:1551–60.

    Article  CAS  Google Scholar 

  15. Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency and toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med. 2013;187:1374–81.

    Article  Google Scholar 

  16. Aksamit TR, O’Donnell AE, Barker A, Olivier KL, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151:982–92.

    Article  Google Scholar 

  17. Lin J-L, Xu J-F, Qu J-M. Bronchiectasis in China. Ann Am Thorac Soc. 2016;5:609–16.

    Article  Google Scholar 

  18. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, et al. An official ATS/ISDA statement: diagnosis, treatment and prevention of Nontuberculous mycobacterial disease. Am J Respir Crit Care Med. 2007;175:367–416.

    Article  CAS  Google Scholar 

  19. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct pre-existing syndrome. Am J Respir Crit Care Med. 2008;178:1066–74.

    Article  CAS  Google Scholar 

  20. Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest. 2010;137:629–34.

    Article  Google Scholar 

  21. O’Connell ML, Birkenkamp KE, Kleiner DE, et al. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest. 2012;141:1203–9.

    Article  Google Scholar 

  22. Fujita J, Ohtsuki Y, Shigeto E, et al. Pathologic findings of bronchiectasis caused by mycobacterium avium intracellulare complex. Respir Med. 2003;97:933–8.

    Article  Google Scholar 

  23. Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–82.

    Article  Google Scholar 

  24. Shimon G, Yonit WW, Gabriel I, et al. The “tree in bud” pattern on chest CT: radiologic and microbiologic correlation. Lung. 2015;193:823–9.

    Article  Google Scholar 

  25. Miller WT, Panosian JS. Causes and imaging patterns of tree-in-bud opacities. Chest. 2013;144:1883–92.

    Article  Google Scholar 

  26. DelGuidice G, Bianco A, Cennamo A, et al. Lung and nodal involvement in nontuberculous mycobacterial disease: PET/CT role. Biomed Res Int. 2015;25:8. https://dx.doi.org/10.1155/2105/353202

  27. Martinez-Garcia M-A, de la Rosa Carrillo D, Soler-Cataluna J-J, et al. Prognostic value of bronchiectasis in patients with moderate-to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823–31.

    Article  CAS  Google Scholar 

  28. Vinnard C, Longworth S, Mezochow A, et al. Deaths related to non-tuberculous mycobacterial infections in the United States, 1999–2014. Ann Am Thorac Soc. 2016;13:1951–55.

    Google Scholar 

  29. Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing harmful effects of non-tuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2016;15:380–5.

    Article  CAS  Google Scholar 

  30. Yamasaki K, Mukae H, Kawanami T, et al. Possible role of anaerobes in the pathogenesis of nontuberculous mycobacterial infection. Respirology. 2015;20:758–65.

    Article  Google Scholar 

  31. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2:988–96.

    Article  CAS  Google Scholar 

  32. Dirac MA, Horan KL, Doody DR, Meschke JS, et al. Environment or host? A case-control study of risk factors for mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186:684–91.

    Article  Google Scholar 

  33. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, et al. Clinical and molecular analysis of macrolide resistance in mycobacterium avium complex lung infection. Am J Respir Crit Care Med. 2006;174:928–34.

    Article  CAS  Google Scholar 

  34. Smith AR, Bell SC, Bojcin S, Bryon M, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13:S23–42.

    Article  Google Scholar 

  35. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:i1–58.

    Article  Google Scholar 

  36. Volsko TA. Airway clearance therapy: finding the evidence. Respir Care. 2013;58:1669–78.

    Article  Google Scholar 

  37. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long term hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.

    Article  CAS  Google Scholar 

  38. Kellett F, Robert NM. Nebulised 7% saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105:1831–5.

    Article  Google Scholar 

  39. Hill AT. Macrolides for clinically significant bronchiectasis in adults: who should receive this treatment? Chest. 2016;150:1187–93.

    Article  Google Scholar 

  40. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infection and associated chronic macrolide use among patients with cystic fibrosis. Am J Respir Crit Care Med. 2013;188:807–12.

    Article  Google Scholar 

  41. Elborn JS, Tunney MM. Macrolides and bronchiectasis. Clinical benefit with a resistance price. JAMA. 2013;309:1295–6.

    Article  CAS  Google Scholar 

  42. Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, Roman-Sanchez P, Perpina Tordera M. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141:461–8.

    Article  CAS  Google Scholar 

  43. Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther. 2012;12:685–700.

    Article  CAS  Google Scholar 

  44. Quinti I, Soresina A, Geurra A, Rondelli R, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcomes in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.

    Article  CAS  Google Scholar 

  45. Koh WJ, Lee JH, Kwon YS, Lee KS, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest. 2007;131:1825–30.

    Article  Google Scholar 

  46. Henkle E, Aksamit T, Barker A, Daley CL, et al. Patient-centered research priorities for pulmonary nontuberculous mycobacterial (NTM) infection. An NTM research consortium workshop report. Ann Am Thorac Soc. 2016;13:S379–84.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center, Washington, DC, USA

    Anne E. O’Donnell

Authors
  1. Anne E. O’Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne E. O’Donnell .

Editor information

Editors and Affiliations

  1. Professor of Medicine, University of Texas Health Science Center, Tyler, TX, USA

    David E. Griffith

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

O’Donnell, A.E. (2019). Management of Lung Diseases Associated with NTM Infection. In: Griffith, D. (eds) Nontuberculous Mycobacterial Disease. Respiratory Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-93473-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93473-0_14

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-93472-3

  • Online ISBN: 978-3-319-93473-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation